Anticoagulation Real World Data

Ray WA., et al,
Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation. JAMA.
2021 Dec 21

Noseworthy PA., et al,
Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation. Chest.
2016 Dec

Yao X., et al,
Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation. J Am Heart Assoc.
2016 Jun 13

Li X., et al,
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS One.
2018 Jan 26

Jaksa A., et al,
Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study. BMJ Open.
2022 Oct 17

Li X., et al,
Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: Comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS One.
2018 Jan 26

Buckley BJR., et al,
Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. J Clin Med.
2022 Jun 30

Lip GYH., et al,
Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients. Stroke.
2018 Dec

Dawwas GK., et al,
Apixaban Versus Rivaroxaban in Patients With Atrial Fibrillation and Valvular Heart Disease: A Population-Based Study. Ann Intern Med.
2022 Nov

Van Ganse E., et al,
Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation: The NAXOS Study. Stroke.
2020 Jul

Perreault S., et al,
Comparative effectiveness and safety of high-dose rivaroxaban and apixaban for atrial fibrillation: A propensity score-matched cohort study. Pharmacotherapy.
2021 Apr

Dhamane AD., et al,
Effectiveness and Safety of Direct Oral Anticoagulants Among Patients with Non-valvular Atrial Fibrillation and Multimorbidity. Adv Ther.
2022 Dec 17

Chao TF., et al,
Oral anticoagulants in extremely-high-risk, very elderly (>90 years) patients with atrial fibrillation. Heart Rhythm.
2021 Jun

Grymonprez M., et al,
Effectiveness and Safety of Oral Anticoagulants in Older Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Front Pharmacol.
2020 Sep 9

Frost C., et al,
Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol.
2013 Nov

Vrijens B., et al,
Non-vitamin K antagonist oral anticoagulants: considerations on once- vs. twice-daily regimens and their potential impact on medication adherence. Europace.
2015 Apr

Deitelzweig S., et al,
Real-world persistence to direct oral anticoagulants in patients with atrial fibrillation: a systematic review and network meta-analysis. Curr Med Res Opin.
2021 Jun

Polymeris AA., et al,
Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation.
Eur Stroke J.
2022 Sep

Durand M., et al,
Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi-database cohort study with meta-analysis. Br J Clin Pharmacol.
2021 Jun

Fralick M., et al,
Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice: A Cohort Study. Ann Intern Med.
2020 Apr 7

Abraham NS., et al,
Gastrointestinal Safety of Direct Oral Anticoagulants: A Large Population-Based Study. Gastroenterology.
2017 Apr

Lau WCY., et al,
Comparative Effectiveness and Safety Between Apixaban, Dabigatran, Edoxaban, and Rivaroxaban Among Patients With Atrial Fibrillation : A Multinational Population-Based Cohort Study. Ann Intern Med.
2022 Nov

Halvorsen S., et al,
Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study. Eur Heart J Qual Care Clin Outcomes.
2022 Aug 17

Ingason AB., et al,
Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants : A Nationwide Propensity Score-Weighted Study. Ann Intern Med.
2021 Nov

Yao X., et al,
Comparative Effectiveness and Safety of Oral Anticoagulants Across Kidney Function in Patients With Atrial Fibrillation. Circ Cardiovasc Qual Outcomes.
2020 Oct

Rao MP., et al,
Clinical Outcomes and History of Fall in Patients with Atrial Fibrillation Treated with Oral Anticoagulation: Insights From the ARISTOTLE Trial. Am J Med.
2018 Mar

Kim DH., et al,
Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study. Ann Intern Med.
2021 Jul 20

Lip GYH., et al,
Oral anticoagulants for nonvalvular atrial fibrillation in frail elderly patients: insights from the ARISTOPHANES study. J Intern Med.
2021 Jan

Kim D., et al,
Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation. Stroke.
2022 Jun

Arbel A., et al,
Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. Br J Clin Pharmacol.
2021 May 13

Arbel R, et al,
Adherence with direct oral anticoagulants in patients with atrial fibrillation: Trends, risk factors, and outcomes. Journal of Arrhythmia.
2021

Angel Y., et al,
Hospitalization as an opportunity to correct errors in anticoagulant treatment in patients with atrial fibrillation. Br J Clin Pharmacol.
2019 Dec

Arbel R., et al,
Direct oral anticoagulation and mortality in moderate to high-risk atrial fibrillation. Heart.
2019 Oct

Yao X., et al,
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc.
2016 Feb 23

Yao X., et al,
Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. J Am Heart Assoc.
2016 Feb 23

Pham PN., et al,
Real-world adherence for direct oral anticoagulants in a newly diagnosed atrial fibrillation cohort: does the dosing interval matter? BMC Cardiovasc Disord.
2019 Mar 19

Komen JJ., et al,
Long-term persistence and adherence with non-vitamin K oral anticoagulants in patients with atrial fibrillation and their associations with stroke risk. Eur Heart J Cardiovasc Pharmacother.
2021 Apr 9

Danchin N., et al,
Comparative non-persistence in the first year of treatment with oral anticoagulants in patients with atrial fibrillation: A French comprehensive nationwide study. Arch Cardiovasc Dis.
2022 Nov

Ozaki AF., et al,
Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis. Circ Cardiovasc Qual Outcomes.
2020 Mar

Banerjee A., et al,
Adherence and persistence to direct oral anticoagulants in atrial fibrillation: a population-based study. Heart.
2020 Jan

Ruigómez A., et al,
Discontinuation of non-Vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation: a population-based cohort study using primary care data from The Health Improvement Network in the UK. BMJ Open.
2019 Oct 18

Zielinski GD., et al,
Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study. Pharmacoepidemiol Drug Saf.
2021 Aug

Alexander JH., et al,
Apixaban 5 mg Twice Daily and Clinical Outcomes in Patients With Atrial Fibrillation and Advanced Age, Low Body Weight, or High Creatinine: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol.
2016 Sep 1

Deitelzweig S., et al,
Effectiveness and Safety of Oral Anticoagulants among NVAF Patients with Obesity: Insights from the ARISTOPHANES Study. J Clin Med.
2020 May 28